Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Qrons Inc (QB) | QRON | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.185475 | 0.185475 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.1557 - 0.745 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.185475 | USD |
Qrons Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.58M | 13.44M | 2.74M | 0 | -789k | -0.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Qrons (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QRON Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.185475 | 0.185475 | 0.185475 | 0.185475 | 1,000 | 0.00 | 0.00% |
6 Months | 0.213 | 0.287 | 0.1557 | 0.210872 | 3,777 | -0.02753 | -12.92% |
1 Year | 0.40 | 0.745 | 0.1557 | 0.3925155 | 13,157 | -0.21453 | -53.63% |
3 Years | 0.6799 | 1.00 | 0.1557 | 0.418392 | 5,391 | -0.49443 | -72.72% |
5 Years | 2.00 | 2.95 | 0.1557 | 0.4988757 | 3,924 | -1.81 | -90.73% |
Qrons (QB) Description
The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Qron's approach is to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering for deployment in the fight against neuronal diseases. It accomplishes this by engaging in strategic and partner arrangements with companies and institutions developing these breakthrough technologies. |